The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Cell & Gene
    • Bioprocessing
    • Drug Delivery
    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Regulation & Standards
    • Small Molecules
    • Supply Chain
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • eBooks
    • Content Hubs
Subscribe
Subscribe
The Medicine Maker / Issues / 2026 / July / Moving Beyond Document-Based Validation
Bioprocessing Interviews Regulation & Standards Standards & Regulation Quality & Compliance Technology & Manufacturing Sponsored

Moving Beyond Document-Based Validation

How UCB is improving traceability, audit readiness, and visibility.

07/02/2026 1 min read Video

Share

Slow workflows, fragmented tools, and repeated data entry can make global validation harder to manage and inspections more difficult to prepare for. How can companies create a faster, more traceable process without simply digitizing existing inefficiencies?

Nadia Williams, Head of IT Compliance Solutions at UCB, explains how the company is moving toward a centralized, record-based validation platform. She also discusses UCB’s pilot-led approach to change, ensuring standardization and audit readiness, and the future potential of automation and AI.

Watch the interview.

Newsletters

Receive the latest pharmaceutical news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

Recommended

Related Content

Musings from The Power List: Andres Sirulnik
Development & Clinical Biopharma Interviews
Musings from The Power List: Andres Sirulnik

October 5, 2026

4 min read

Regeneron's L. Andres Sirulnik explains why modernizing clinical trials is as important as developing new medicines

Musings from The Power List: Fabian Gerlinghaus
Development & Clinical Cell & Gene Interviews
Musings from The Power List: Fabian Gerlinghaus

October 1, 2026

3 min read

Cellares Co-Founder and CEO discusses why the future of cell therapy depends on rethinking how therapies are made

Musings from The Power List: Renee Aguiar-Lucander
Biopharma Development & Clinical Interviews
Musings from The Power List: Renee Aguiar-Lucander

September 28, 2026

2 min read

Renee Aguiar-Lucander argues that faster clinical trials and more pragmatic regulation are essential to bringing medicines to patients sooner

Musings from The Power List: Michael May
Cell & Gene Development & Clinical Interviews
Musings from The Power List: Michael May

September 22, 2026

5 min read

CCRM CEO Michael May on quantum computing, commercialization, and the next era of cell therapy

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2026 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

Affiliations:

Specialties:

Areas of Expertise:

Contributions: